CLINICAL STUDY PROTOCOL
CHOICE

CHemical OptImization of Cerebral Embolectomy in patients with acute stroke treated with mechanical thrombectomy (CHOICE TRIAL)

Study Code: CHOICE
Protocol Version 1.0: March 07, 2018
EudraCT Number: 2018-002195-40
SPONSOR: Fundació Clínic per la Recerca Biomèdica
### SUMMARY OF THE TRIAL

<table>
<thead>
<tr>
<th>Title</th>
<th><strong>Chemical Optimization of Cerebral Embolectomy in patients with acute stroke treated with mechanical thrombectomy (CHOICE TRIAL)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Study Design</td>
<td>Multicenter, randomized, placebo-controlled, double blind, phase 2b trial of acute stroke patients treated with MT, in which two therapies are compared: rt-PA or placebo. Allocation at each center will account for 1 stratum: use of alteplase (yes vs. no) before MT. Subjects will be followed up to 90 days post-randomization</td>
</tr>
<tr>
<td>Clinical Site Locations</td>
<td>Catalonia Autonomous Community, Spain</td>
</tr>
</tbody>
</table>
| Study Centers | Hospital Clinic de Barcelona (HC)  
Hospital Universitari de Bellvitge (HB)  
Hospital Vall d’Hebron (HVH)  
Hospital de la Santa Creu i Sant Pau (HSP)  
Hospital del Mar (HM)  
Hospital Germans Trias i Pujol (HGTP) |
| Study Objective | The study objective is to evaluate whether rt-PA is safe and efficient as an add-on to mechanical thrombectomy in patients with acute ischemic stroke and complete or near-complete recanalization of a proximal vessel occlusion but partial brain reperfusion on cerebral angiogram >50% and <91% brain reperfusion on cerebral angiography (corresponding to mTICI score 2b) |
| Subject Population | Patients with symptomatic large vessel occlusion (LVO) in the anterior circulation treated with MT resulting in a mTICI score 2b at end of the procedure |
| Enrolment | Patients will be enrolled in the angiosuit by interventionalists or neurologists once a mTICI 2b is confirmed at the end of a routinely performed endovascular procedure.  
A sample size of 100 patients per treatment arm in a 1:1 allocation will have >95% statistical power for |
the primary outcome (5% of improved TICI score control vs 60% in experimental) for a two-sided 5% alpha, taken into account a 5% of the sample lost to follow up. This sample size will also guarantee around 80% power for most of the secondary outcomes with at least 90 valid patients per arm.

<table>
<thead>
<tr>
<th>Follow-up</th>
<th>Each patient included will be followed up to 90 days from the stroke</th>
</tr>
</thead>
</table>

| Inclusion Criteria | 1. Patients with symptomatic large vessel occlusion (LVO) in the anterior, middle or posterior cerebral arteries treated with MT resulting in a mTICI score 2b at end of the procedure  
2. Estimated delay to onset of rescue intraarterial rt-PA or placebo administration <24 hours from symptom onset, defined as the point in time the patient was last seen well  
3. No significant pre-stroke functional disability (modified Rankin scale 0-1)  
4. Age ≥18  
5. ASPECTS ≥6 on non-contrast CT (NCCT) scan if symptoms lasting <4.5 hours or ASPECTS >6 on CT-Perfusion (CTP) if symptoms ≥4.5 <24 hours. In both cases, ASPECTS is obtained within <75 minutes of the onset of mechanical thrombectomy  
6. Informed consent obtained from patient or acceptable patient surrogate |

| Exclusion Criteria | 1. NIHSS score on admission ≥25  
2. Contraindication to IV t-PA as per local national guidelines (except time to therapy)  
3. Use of carotid artery stents during the endovascular procedure requiring dual antiplatelet therapy  
4. Female who is pregnant or lactating or has a positive pregnancy test at time of admission  
5. Current participation in another investigation |
<table>
<thead>
<tr>
<th>Study Drug or Device Treatment Study  (except observational study i.e.: RACECAT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency</td>
</tr>
<tr>
<td>7. Known coagulopathy, INR &gt;1.7 or use of novel anticoagulants &lt;12h from symptom onset</td>
</tr>
<tr>
<td>8. Platelets &lt;50,000</td>
</tr>
<tr>
<td>9. Renal Failure as defined by a serum creatinine &gt;3.0 mg/dl (or 265.2 μmol/l) or glomerular Filtration Rate [GFR] &lt;30</td>
</tr>
<tr>
<td>10. Subject who requires hemodialysis or peritoneal dialysis, or who have a contraindication to an angiogram for whatever reason</td>
</tr>
<tr>
<td>11. Any hemorrhage on CT/MRI</td>
</tr>
<tr>
<td>12. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal</td>
</tr>
<tr>
<td>13. Suspicion of aortic dissection</td>
</tr>
<tr>
<td>14. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol</td>
</tr>
<tr>
<td>15. History of life threatening allergy (more than rash) to contrast medium</td>
</tr>
<tr>
<td>16. SBP &gt;185 mmHg or DBP &gt;110 mmHg refractory to treatment</td>
</tr>
<tr>
<td>17. Serious, advanced, terminal illness with anticipated life expectancy &lt;6 months</td>
</tr>
<tr>
<td>18. Pre-existing neurological or psychiatric disease that would confound evaluation</td>
</tr>
<tr>
<td>19. Presumed vasculitis or septic embolization</td>
</tr>
<tr>
<td>20. Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas)</td>
</tr>
</tbody>
</table>

**Primary Outcome**
- Proportion of patients with an improved mTICI score ten (10) minutes after the end of the experimental study treatment.

**Analysis**
- The statistical analysis will be carried out in accordance with the principles specified in the
<table>
<thead>
<tr>
<th>Topic</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Conference on Harmonization (ICH)</td>
<td>Topic E9 (CPMP / ICH / 363/96)</td>
</tr>
<tr>
<td>Safety endpoints</td>
<td>1. Mortality at 90 days</td>
</tr>
<tr>
<td></td>
<td>2. sICH rates at 24 hours</td>
</tr>
<tr>
<td>Study Timeline</td>
<td>Recruitment period estimated in 24 months</td>
</tr>
<tr>
<td></td>
<td>F-up per patient: 3 months</td>
</tr>
<tr>
<td>Primary Analysis</td>
<td>The primary outcome will be estimated using a log-binomial regression model including the stratification variables, except centre. In the unexpected event that the model does not fit, the Poisson regression model with long-link and robust variance estimator will be used instead.</td>
</tr>
<tr>
<td>Steering Committee</td>
<td>Angel Chamorro (Chair)</td>
</tr>
<tr>
<td></td>
<td>Sergio Amaro</td>
</tr>
<tr>
<td></td>
<td>Pere Cardona</td>
</tr>
<tr>
<td></td>
<td>Antonio Dávalos</td>
</tr>
<tr>
<td></td>
<td>Juan Macho</td>
</tr>
<tr>
<td></td>
<td>Joan Martí-Fábregas</td>
</tr>
<tr>
<td></td>
<td>Carlos Molina</td>
</tr>
<tr>
<td></td>
<td>Laura Oleaga</td>
</tr>
<tr>
<td></td>
<td>Jaume Roquer</td>
</tr>
<tr>
<td></td>
<td>Ferran Torres (Biostatistician)</td>
</tr>
<tr>
<td></td>
<td>Xabier Urra</td>
</tr>
<tr>
<td>Neuroimaging Core Lab</td>
<td>Luis San Román (Chair)</td>
</tr>
<tr>
<td></td>
<td>Antonio López</td>
</tr>
<tr>
<td></td>
<td>Arturo Renú</td>
</tr>
<tr>
<td></td>
<td>Carlos Laredo</td>
</tr>
<tr>
<td>Neurointerventionalism</td>
<td>Jordi Blasco (Chair)</td>
</tr>
<tr>
<td>Harmonization</td>
<td>Alejandro Tomasello</td>
</tr>
<tr>
<td></td>
<td>Polo Guimaraes</td>
</tr>
<tr>
<td></td>
<td>Roger Barranco</td>
</tr>
<tr>
<td></td>
<td>Carlos Castaño</td>
</tr>
<tr>
<td>Patient’s recruitment Board</td>
<td>Mónica Millán (Chair)</td>
</tr>
<tr>
<td></td>
<td>Marián Muchada</td>
</tr>
<tr>
<td></td>
<td>Elisa Cuadrado</td>
</tr>
<tr>
<td>Clinical Study Management</td>
<td>ANAGRAM-ESIC</td>
</tr>
</tbody>
</table>
| **Data Safety Monitoring Board (DSMB)** | Dr. Tudor Jovin (Chair). University of Pittsburgh  
|                                         | Dr. Enrique Leira. University of Iowa  
|                                         | Dr. José Ríos (Biostatistician) Autonomous University of Barcelona |
| **Data Management - eCRF - Statistics** | IDIBAPS - Hospital Clinic Barcelona |
| **Sponsor**                            | Fundació Clínic per la Recerca Biomèdica |
TABLE OF CONTENTS

SUMARY OF THE TRIAL. ........................................................................................................ 2
TABLE OF CONTENTS .......................................................................................................... 7
PROTOCOL SIGNATURE PAGE SPONSOR AND CHAIRMAN ........................................... 9
PROTOCOL SIGNATURE PAGE PRINCIPAL INVESTIGATOR ........................................... 10
1. ADMINISTRATIVE INFORMATION .................................................................................. 11
2. INTRODUCTION .............................................................................................................. 13
   2.1 Background and rationale ............................................................................................. 13
      2.1.1 Overview of reperfusion therapy in acute ischemic stroke .................................. 13
      2.1.2 Maximizing brain reperfusion: a target for treatment improvement .................. 17
      2.1.3 Justification of CHOICE ..................................................................................... 17
   2.2 OBJECTIVES ................................................................................................................ 19
   2.3 TRIAL DESIGN ............................................................................................................ 19
3. METHODS ........................................................................................................................ 19
   3.1 STUDY SETTING .......................................................................................................... 19
   3.2 ELEGIBILITY CRITERIA ............................................................................................... 19
      3.2.1 Inclusion Criteria .................................................................................................... 19
      3.2.2 Exclusion Criteria ................................................................................................ 20
      3.2.3 Brain Imaging ........................................................................................................ 21
   3.3 INTERVENTIONS .......................................................................................................... 21
      3.3.1 Blinding .................................................................................................................. 22
      3.3.2 Concomitant care and interventions prohibited during the trial ......................... 22
   3.4 ASSIGNMENT OF INTERVENTION. ALLOCATIONS AND SEQUENCE GENERATION ........................................................................................................... 23
   3.5 OUTCOMES ................................................................................................................... 23
      3.5.1 Primary outcome .................................................................................................... 23
      3.5.2 Secondary outcomes ............................................................................................. 23
      3.5.3 Tertiary outcomes ............................................................................................... 23
      3.5.4 Pre-specified subgroup analysis .......................................................................... 23
      3.5.5 Safety outcomes ................................................................................................... 24
      3.5.6 Adverse events (AEs) and Serious Adverse Events (SAEs) .................................. 24
         3.5.6.1 Definitions and Classification ........................................................................ 24
         3.5.6.2 Recording of AEs and SAEs .......................................................................... 25
         3.5.6.3 Prompt Reporting of SAEs ............................................................................ 26
         3.5.6.4 Evaluating AEs and SAEs ............................................................................. 26
         3.5.6.4.1 Assessment of Intensity .......................................................................... 26
         3.5.6.4.2 Assessment of Causality ........................................................................ 27
3.5.6.4.3 Assessment of Expectedness ........................................................... 27
3.5.6.4.4 Follow-up of AEs and SAEs .............................................................. 28

3.6 STATISTICAL METHODS ................................................................. 28
3.6.1 General Remarks ........................................................................... 28
3.6.2 Sample size calculation ................................................................. 28
3.6.3 Data Blind Review (DBR) ............................................................... 29
3.6.4 Analysis populations .................................................................... 29
3.6.5 Randomisation Procedure .............................................................. 30
3.6.6 Inferential Analysis ........................................................................ 30
  3.6.6.1 Primary endpoint .................................................................... 30
  3.6.6.2 Secondary endpoints and safety outcomes ............................... 30
  3.6.6.3 General strategy for the rest of variables ................................. 31
3.6.7 Multiplicity adjustments and interim analysis ................................. 31
3.6.8 Handling of missing data ............................................................... 32
3.6.9 Subgroup analysis ......................................................................... 32

3.7 STUDY FEASIBILITY ....................................................................... 33

4. DATA MANAGEMENT/MONITORING AND QUALITY CONTROL ........ 33
4.1 Data collection methods .................................................................... 33
4.2 Data management .............................................................................. 33
4.3 Data monitoring .................................................................................. 34
4.4 Screening log ..................................................................................... 35
4.5 Data auditing ....................................................................................... 35
4.6 Independent committees ..................................................................... 35
4.7 Training of investigators and site personnel ...................................... 36

5. ETHICS AND DISSEMINATION ......................................................... 36
5.1 Research Ethics approval ................................................................... 36
5.2 Consent ............................................................................................ 37
5.3 Confidentiality ................................................................................... 37
5.4 Record Retention ............................................................................... 38
5.5 Dissemination policy .......................................................................... 38

6. APPENDIXES ..................................................................................... 39
6.1 Abbreviations and Acronyms ............................................................ 39
6.2 Informed consent ............................................................................... 41
6.3 Modified Rankin scale (structured phone-based interview) ............ 42
6.4 Angiographic assessment: The mTICI score .................................. 44
6.5 Study Assessments ........................................................................... 47
6.6 Bibliography ...................................................................................... 48
STUDY CODE: CHOICE

Study titled: A phase 2b trial comparing the administration of alteplase or placebo for Reperfusion Injury Control in acute stroke patients secondary to large vessel occlusion treated with mechanical thrombectomy

The signatures on this page indicate review and approval of the final version of the protocol.

By signing this document we confirm that the clinical study will be conducted in accordance with the protocol and all applicable laws and regulations including, but not limited to, the International Conference on Harmonization Guideline for Good Clinical Practice (GCP) and the ethical principles that have their origins in the Declaration of Helsinki.

_______________________     _________________
Dr. Ángel Chamorro          Date of signature
Chairman/ Sponsor’s Representative Name
PROTOCOL SIGNATURE PAGE PRINCIPAL INVESTIGATOR

STUDY CODE: CHOICE

Study titled: CHemical Optimization of Intraarterial Cerebral Embolectomy in acute stroke patients treated with mechanical thrombectomy

The signatures on this page indicate review and approval of the final version of the protocol.

By signing this document we confirm that the clinical study will be conducted in accordance with the protocol and all applicable laws and regulations including, but not limited to, the International Conference on Harmonization Guideline for Good Clinical Practice (GCP) and the ethical principles that have their origins in the Declaration of Helsinki.

_________________________
Principal Investigator’s Name

________________                             ________________
Signature       Date of signature
1. ADMINISTRATIVE INFORMATION

Title: CHEmical OptImlization of Cerebral Embolectomy in patients with acute stroke treated with mechanical thrombectomy (CHOICE TRIAL)

Protocol version: Version 1, March 7, 2018

Funding: Marató de TV3

Study Steering Committee

Ángel Chamorro. Neurologist (Chair), Hospital Clínic, Barcelona
Sergio Amaro. Neurologist, Hospital Clínic, Barcelona
Pere Cardona. Neurologist, Service of Neurology, Hospital de Bellvitge, Barcelona
Antonio Dávalos. Neurologist, Hospital Germans Trias I Pujol, Badalona
Juan Macho. Neurointerventionalist, Hospital Clínic Barcelona
Joan Martí-Fábregas, Neurologist, Hospital Sant Pau, Barcelona
Carlos Molina. Neurologist, Service of Neurology, Hospital Vall de Hebrón, Barcelona
Laura Oleaga. Neuroradiologist, Hospital Clínic, Barcelona
Jaume Roquer. Neurologist, Service of Neurology, Hospital del Mar, Barcelona
Ferran Torres. Biostatistician, Hospital Clínic, Barcelona
Xabier Urra. Neurologist, Hospital Clínic, Barcelona

Sponsor

Fundació Clínic per a la Recerca Biomèdica
Roselló, 149-153
otri@clinic.cat

Data and Safety Monitoring Board (DSMB)

Tudor Jovin (Chair). Neurointerventionalist, University of Pittsburgh
Enrique Leira. Neurologist. University of Iowa
José Ríos, Biostatistics Unit. Autonomous University of Barcelona

Neuroimaging Core Lab

Luis San Román (Chair). Neurointerventionalist, Hospital Clínic, Barcelona
Antonio López. Neurointerventionalist, Hospital Clínic, Barcelona
Arturo Renú. Neurologist, Hospital Clínic, Barcelona
Carlos Laredo, Physicist, Hospital Clínic, Barcelona
Neurointerventionalism Harmonization

Jordi Blasco (Chair). Neurointerventionalist, Hospital Clínic, Barcelona
Alejandro Tomasello. Neurointerventionalist, Hospital Vall de Hebrón, Barcelona
Polo Guimaraes. Hospital del Mar, Barcelona
Roger Barranco. Hospital de Bellvitge, Barcelona
Carlos Castaño, Neurointerventionalist, Hospital Germans Trias i Pujol, Badalona

Patient’s recruitment Board

Mónica Millán (Chair), Neurologist, Hospital Germans Trias i Pujol, Badalona
Marián Muchada, Neurologist, Hospital Vall de Hebrón, Barcelona
Elisa Cuadrado, Neurologist, Hospital del Mar, Barcelona

Funder and Sponsor of the CHOICE trial will have no influence on the study design, collection, management, analysis and interpretation of data, writing of the report and decision to submit the report for publication. Chairs and members of the Executive Committee will perform all these activities.
2. INTRODUCTION

Stroke represents the second single most frequent cause of death for people older than 60 years, the most frequent cause of permanent disability, and the second most common cause of dementia, and uses approximately 3–7% of the total health-care expenditure in high-income countries. By 2050, more than 1.5 billion people in the world will be aged 65 years or older and the global burden of stroke will keep increasing in parallel with the ageing population. Although a remarkable progress has been made in the management of patients with acute ischemic stroke during the past 10 years, with the widespread implementation of specialist stroke units, evidence of the efficacy of intravenous (IV) thrombolytic treatment, and reporting of randomized controlled trials (RCTs) establishing the value of endovascular thrombectomy, stroke still represents the first cause of permanent disability in adult people. In consequence, there is a pressing need to continue investigating new treatments for this devastating disease.

2.1 Background and rationale

2.1.1 Overview of reperfusion therapy in acute ischemic stroke

Intravascular thrombosis remains a leading cause of death and disability for which thrombolysis is the only pharmacological remedy. The thrombolytic, rt-PA, has become essentially synonymous with thrombolysis but its use, or that of one of its longer half-life derivates, has been declining due to its inadequate efficacy in AMI, incompatibility with PCI, limited efficacy and risk of ICH in ischemic stroke, and too high a bleeding risk for most patients with venous thromboembolism. Instead, intra-arterial devices have become the treatment of choice in AMI are becoming more frequently used in ischemic stroke as well. The resort to these time-consuming methods to treat very time-sensitive conditions is a reflection on the inadequacy of current thrombolysis.

The main aim of acute ischemic stroke treatment is to salvage the penumbra or volume of hypo-perfused, non-functional, yet still viable tissue surrounding the infarcted core, and several reperfusion therapies have shown positive clinical results. A meta-analysis of individual patient data from nine randomized trials comparing intravenous alteplase with placebo or open control showed that alteplase increased the odds of a good stroke outcome (i.e., a modified Rankin scale score of zero or one at 3–6 months), with earlier treatment associated with bigger proportional benefit. Accordingly, rapid administration of IV recombinant tissue-type plasminogen activator (rt-PA) to appropriate patients remains the mainstay of early treatment of acute ischemic stroke. However, IV rt-PA induces recanalization in only 40% of the cases, and this rate is even lower in occlusions of the
M1 segment of the middle cerebral artery or the intracranial internal carotid artery, where the rate of recanalization is approximately 20% and 10%, respectively.

IA thrombolysis involves administration of high concentrations of thrombolytic agents near the thrombus, utilizing lower doses than systemic administration, which may result in lower systemic complications, and less local neurotoxic effects of thrombolytic agents. The disadvantages of the IA modality include the potential delay required to obtain initial cerebral angiography and position of the micro-catheter for administration of the thrombolytic agent. IA thrombolysis also allows the simultaneous use of mechanical devices to facilitate thrombolysis, and combining the IA delivery with mechanical thrombectomy (MT) increases the surface area exposed to the thrombolytic agents. The concern of delaying treatment onset using the IA route alone led to the initiative of delivering the IA thrombolysis following IV thrombolysis. Thus, the Emergency Management of Stroke (EMS) bridging trial, which had a randomized, double-blind, placebo control design, demonstrated higher recanalization rates (53%) in the combined IV/IA alteplase treatment group than in the IA alteplase group (28%). In this study, 35 patients were treated within 3 hours of symptom onset and received IV rt-PA (0.6 mg/kg, 60 mg maximum, 10% of the dose as a bolus over 1 minute and the remainder over 30 minutes) or placebo. This was followed by immediate cerebral angiography and local IA administration of rt-PA through the catheter if a clot in the appropriate arterial distribution was identified. A maximum local IA dose of 20 mg was given and the infusion was continued for a maximum of 2 hours. In EMS, there was no difference in clinical outcomes between the 2 groups and no significant difference in the rate of symptomatic ICH. Indeed, there were no parenchymal hematomas in the trial; symptomatic ICH within 24 hours occurred in 1 placebo/IA patient only; beyond 24 hours, symptomatic ICH occurred in 2 IV/IA patients only.

The Interventional Management of Stroke Trial III (IMS III) was a PROBE, 2-arm, superiority trial that enrolled 656 patients with a major ischemic stroke who received IV rt-PA within 3 hours of stroke onset. Patients were randomly allocated 1:2 to standard dose IV rt-PA (0.9 mg/kg) or to IV rt-PA 0.6 mg/kg followed by endovascular therapy with a device and/or IA rt-PA, if occlusion persisted and if the endovascular intervention could be begun within 5 hours and completed within 7 hours of onset. For subjects who the study neurointerventionalist elected to treat with the standard micro-catheter infusion of rt-PA, as in the IMS I Pilot Trial, the rt-PA concentration for IA administration was 0.5 mg/1 ml solution (50 mg/100 cc - reconstituted with 50 cc of sterile water without preservatives and diluted to 100 cc total with 50 cc normal saline). A maximum IA dose of 22 mg was administered over two hours of infusion. The trial was stopped early for futility after 656 of
projected 900 subjects were enrolled. There was no significant difference in outcome between the IV rt-PA only group and the endovascular group for the primary end point of the percentage of patients with a good outcome as measured by modified Rankin Scale (mRS) score of 0 to 2 or for death at 90 days. Findings in the endovascular-therapy and intravenous rt-PA groups were similar for mortality at 90 days (19.1% and 21.6%, respectively; P = 0.52) and the proportion of patients with symptomatic intracerebral hemorrhage within 30 hours after initiation of t-PA (6.2% and 5.9%, respectively; P = 0.83). Yet, the IMS III trial showed that the proportion of patients who obtained a mRS score of 2 or less at 90 days of the therapy (primary outcome of the study) increased in parallel with the magnitude of reperfusion measured using the Thrombolysis In Cerebral Infarction (TICI) grade. Thus, the primary outcome occurred in 12.7% of the 55 patients with a TICI score of 0, in 27.6% of the 29 patients with a TICI score of 1, in 34.3% of the 108 patients with a TICI score of 2a, in 47.9% of the 119 patients with a TICI score of 2b, and in 71.4% of the 7 patients with a TICI score of 3 (P<0.001). These results highlight the importance of obtaining complete brain reperfusion to maximize the benefits of mechanical thrombectomy.

Prior small case series have demonstrated that IA therapy with thrombolytic agents, Mechanical Clot Disruption (MCD), or a combination of IA thrombolytic agents with MCD are safe and effective with and without prior full-dose IVT in restoring flow in acute large artery occlusions. Nine IA thrombolytic agents, when used in low doses, have been found to be safe in conjunction with MCD. A series of 8 patients suggested that an IA rt-PA dose up to 40 mg is safe, but these patients did not receive prior IVT. The overall efficacy and safety of IA versus IV thrombolysis in patients with acute ischemic stroke was updated in a recent meta-analysis that showed that IA thrombolysis in patients was significantly more likely to result in a favorable outcome than was IVT. However, other meta-analyses using different study selection criteria found no significant benefit of IA over IV. Altogether, IA thrombolysis initiated within 6 h of stroke onset might be considered in carefully selected patients who have contraindications to the use of IV alteplase, although alteplase does not have US Food and Drug Administration approval for intra-arterial use, and the adverse effects associated with this administration route have yet to be established. Unfortunately, there are no published reports of observational or randomized studies of IA thrombolysis performed after MT to attempt improving the perfusion rate of territories distal to the proximal arterial occlusion.

In 2015, several RCTs showed that MT results in complete vessel recanalization in three of four treated patients, and this treatment was superior to IV alteplase in improving stroke outcomes in selected patients with large proximal artery occlusions.
comprehensive systematic review and meta-analysis of eight RCTs (totaling 2049 patients) confirmed that MT was associated with an increased likelihood of good outcome (i.e., a modified Rankin scale score of zero to two at 90 days) compared with standard alteplase treatment. Patients receiving alteplase before MT also had a significant improvement in outcome compared with patients who received only one of these treatment approaches (Yarbrough et al. 2015). MT in combination with IA pharmacologic thrombolysis has been associated with higher rates of recanalization. In a recent individual patient data meta-analysis by the HERMES group of patients with large-vessel ischemic stroke, earlier treatment with MT + medical therapy compared with medical therapy alone was associated with lower degrees of disability at 3 months and the clinical benefit became non-significant after 7.3 hours. More recently, the DAWN (Diffusion weighted imaging (DWI) or computerized tomography perfusion (CTP) assessment with clinical mismatch in the triage of wake up and late presenting strokes undergoing neuro-intervention with Trevo) data was reported. Patients with wake-up and late-presenting stroke were screened and if they met the inclusion criteria (age ≥18 years, NIHSS ≥10, pre-mRS 0–1, time-last-seen-well to randomization 6–24 hours, excluding large infarcts and confirmation of large vessel occlusion on CTA or MRA) underwent imaging with the RAPID software, CTP or DWI. Qualifying patients had to meet the following clinical imaging mismatch criteria: patients’ age ≥80 years old had to have NIHSS ≥10 with a core <21cc; <80 year old patients had to have NIHSS ≥10 with a core of <31cc or NIHSS ≥20 with a core of <51cc. The symptomatic intracerebral hemorrhage (sICH) rate was 4.8% in the treatment arm versus 3.2% in the control arm. A statistically significant difference was observed in neurological deterioration (defined as greater than 4 points worse on the NIHSS by five days) between the two groups with 10.5% in the treatment arm versus 22.1% in the control arm (p<0.01).

In the weighted mRS based co-primary outcome, the mean mRS value in the treatment group was 5.5 versus 3.4 in the control group; a 2.1 difference in the weighted mRS score, which is highly significant with a Bayesian probability of superiority of >0.9999 (which is similar to p<0.0001). The co-primary endpoint of 90-day functional independence was 48.6% in the treatment group versus 13.1% in the control group; a 35.5% actual difference, which is highly significant with a Bayesian probability of superiority of >0.9999. This translates to a number needed to treat of 2.8 to achieve functional independence.

Despite the unquestionable value of current reperfusion therapies less than half of the patients that receive MT show permanent benefits. A likely relevant reason to these insufficient clinical benefits is the lack of adequate brain reperfusion despite successful recanalization (futile recanalization). In the recent endovascular trials, "successful" brain reperfusion occurred in 75% of treated patients, including a group of 37% of patients who obtained complete reperfusion (mTICI 3 score) and a group of 38% of patients who
obtained only near complete reperfusion (mTICI 2b score) at the end of the procedure. Although several studies have shown a graded association between the amount of brain tissue re-perfused and the degree of clinical benefit, the most recent endovascular trials did not report individual stroke outcomes amongst patients with mTICI 2b or 3 scores.

2.1.2 Maximizing brain reperfusion: a target for treatment improvement

Structural and functional alterations in the microvasculature may be major barriers for adequate reperfusion of the ischemic brain regardless of complete recanalization and constitute the no-reflow phenomenon. In experimental models, downstream microvascular thrombosis (DMT) may occur early during brain ischemia and before recanalization, and this mechanism may be a major contributing factor to incomplete reperfusion. It is possible that a similar mechanism may limit the therapeutic potential of MT in patients with acute stroke. Originally attributed to spasm or cellular swelling around the vessel wall, the no reflow phenomenon is currently ascribed to microvascular clogging triggered by neutrophils trapped within the microcirculation, clogging of the perivascular space, distal micro-embolism, and oxidative stress generated in pericytes or arteriolar smooth muscle cells. In experimental studies, this clogging was prevented or reversed using genetic or pharmacological manipulations of cell mediated inflammation, but these measures were futile or harmful at the bedside. Considering the nature of these mechanisms, we believe that IA thrombolytic therapy is a pharmacological approach that deserves adequate testing in patients with incomplete reperfusion following MT. Mechanical embolus retrieval does recanalize the occluded larger arteries without considering the status of the distal smaller arteries. However, recanalization of the primary arterial occlusive lesion does not necessarily translate into reperfusion of ischemic tissue through the distal capillaries. IA pharmacologic therapy remains the only possible alternative in such situations to ensure complete angiographic reperfusion to the ischemic tissue.

2.1.3 Justification of CHOICE

While previous studies of improving brain reperfusion using IA thrombolytic therapy were done before the recanalization of a proximal LVO, in this project we intend to administer IA thrombolysis after the successful recanalization of a LVO. Indeed, this temporal approach might prove to be crucial to facilitate a greater access of the drug to the distal vascular bed and thus allow a more effective lytic effect on microcirculatory thrombi.

The current guideline for healthcare professionals from the American Heart Association/American Stroke Association (AHA/ASA) states that the use of salvage technical adjuncts including IA fibrinolysis may be reasonable to achieve a satisfactory angiographic result in patients treated with MT (Class IIb recommendation). Yet, the
usefulness, and effectiveness of salvage IA thrombolysis are not well established. The AHA/ASA also recommends that the angiographic technical goal of MT is to achieve a mTICI 2b or 3 scores.\textsuperscript{[20]} Yet, growing evidence shows that combining these two mTICI scores into a single category of angiographic results may be misleading because they may show significant differences in clinical and radiologic outcomes.\textsuperscript{[11,42,43]} To better address this issue, we reviewed recently our own experience, and compared the clinical and radiologic outcomes of patients with a mTICI 3 or a mTICI 2b score at the end of MT.\textsuperscript{44} All these patients received stent-retrievers and pretreatment IV alteplase was administered to approximately one third of the patients. The outcomes were evaluated in multivariate models following the HERMES Collaborators criteria,\textsuperscript{[28]} and the covariates assessed in the models included age, sex, baseline stroke severity, target occlusion location, ASPECTS, pre-treatment IV alteplase, time to recanalization and the collateral score. Between March 2010 and May 2016, 125 of 347 (36%) patients treated with MT at Hospital Clinic of Barcelona met the entry criteria of the study. Contrarily, 222 patients were excluded for (1) a posterior circulation stroke (n = 31); (2) lost to follow-up due to transfer to a referral Primary Stroke Center after MT (n = 113); (3) unavailability of multimodal brain imaging (n = 37); or (4) mTICI 2a/1/0 score at the end of MT (n = 41). Recanalization of the local occlusion occurred within a median (IQR) of 285 (210–369) minutes of symptom onset; 51 (41%) patients achieved an mTICI 2b score and 74 (59%) patients a mTICI 3 score. Patients with final mTICI 2b or 3 scores did not show significant differences in demographics, risk factors, target occlusion location, use of bridging intravenous alteplase before MT, or size of infarct core calculated either with the ASPECTS on NCCT or on CTP (Table 1). Expectedly, a mTICI 3 score was associated with shorter time to recanalization from stroke onset, and less number of device passes. A final mTICI score 3 was more frequent in patients with good leptomeningeal collateral scores, and this association was highly significant in a multivariate model adjusted for the predefined covariates of the study, (odds ratio 2.765 95% CI 1.248–6.123). The primary outcome measure of the study showed that more patients with mTICI 3 were in a better score category on the mRS at 90 days than were patients with mTICI 2b, and this difference was statistically significant in ordinal regression analysis adjusted for confounders (odds ratio 2.018, 95% CI 1.033–3.945).

Excellent outcome at 90 days was reported in 18 (35%) of 51 patients achieving an mTICI 2b score and in 41 (55%) of 74 patients achieving an mTICI 3 score, (adjusted odds ratio 2.739, 95% CI 1.124–6.182). Early dramatic recovery at 24 hours was diagnosed in 25 (49%) patients with mTICI 2b and in 54 (73%) patients with mTICI 3, (adjusted odds ratio 3.078, 95% CI 1.384–6.849). Finally, the mortality and the rate of symptomatic intracerebral hemorrhage did not differ between patients with mTICI 3 or 2b scores. Collectively, this study demonstrated the relevance of achieving an mTICI 3 score at the...
end of MT to maximize the functional benefits of brain reperfusion. Compared with patients with an mTICI 2b score, patients who achieved a mTICI 3 had better overall health transitions in the full range of the mRS, increased proportions of excellent outcome and early dramatic recovery, less infarct growth and smaller final infarcts. Altogether, these results justify the search of more effective reperfusion therapies and call for a change of current practice recommendations in patients treated with MT indicating that only an mTICI 3 angiographic score should be considered success after MT.

2.2 OBJECTIVES
The study objective is to evaluate whether rt-PA is safe and efficient as an add-on to mechanical thrombectomy in patients with acute ischemic stroke and complete or near-complete recanalization of a proximal vessel occlusion but partial brain reperfusion on cerebral angiogram > 50% and < 91% brain reperfusion on cerebral angiography (corresponding to mTICI score 2b).

2.3 TRIAL DESIGN
Multicenter, randomized, placebo-controlled, double blind, phase 2b trial of acute stroke patients treated with MT, in which two therapies are compared: rt-PA or placebo. Allocation at each center will account for 1 stratum: use of alteplase (yes vs. no) before MT. Subjects will be followed up to 90 days post-randomization.

3. METHODS
3.1 STUDY SETTING
The CHOICE trial will be performed in Catalonia Autonomous Community, and it will include six Endovascular Stroke Centers located in Barcelona and Badalona:

1. Hospital Clinic de Barcelona (HC)
2. Hospital Universitari de Bellvitge (HB)
3. Hospital Vall d’Hebron (HVH)
4. Hospital de la Santa Creu i Sant Pau (HSP)
5. Hospital del Mar (HM)
6. Hospital Germans Trias i Pujol (HGTP)

3.2 ELIGIBILITY CRITERIA
3.2.1 Inclusion Criteria
1. Patients with symptomatic large vessel occlusion (LVO) in the anterior, middle or posterior cerebral artery treated with MT resulting in a mTICI score 2b at end of the procedure
2. Estimated delay to onset of rescue intraarterial rt-PA administration <24 hours from symptom onset, defined as the point in time the patient was last seen well
3. No significant pre-stroke functional disability (modified Rankin scale 0-1)
4. Age ≥18
5. ASPECTS ≥6 on non-contrast CT (NCCT) scan if symptoms lasting <4.5 hours or ASPECTS ≥6 on CT-Perfusion (CTP) if symptoms ≥4.5 <24 hours. In both cases, ASPECTS is obtained within <75 minutes of the onset of mechanical thrombectomy.
6. Informed consent obtained from patient or acceptable patient surrogate

3.2.2 Exclusion Criteria
1. NIHSS score on admission >25
2. Contraindication to IV t-PA as per local national guidelines (except time to therapy)
3. Use of carotid artery stents during the endovascular procedure requiring dual antiplatelet therapy
4. Female who is pregnant or lactating or has a positive pregnancy test at time of admission
5. Current participation in another investigation drug or device treatment study (except observational study i.e.: RACECAT)
6. Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency
7. Known coagulopathy, INR > 1.7 or use of novel anticoagulants < 12h from symptom onset
8. Platelets < 50,000
9. Renal Failure as defined by a serum creatinine > 3.0 mg/dl (or 265.2 μmol/l) or glomerular Filtration Rate [GFR] < 30
10. Subject who requires hemodialysis or peritoneal dialysis, or who have a contraindication to an angiogram for whatever reason
11. Any hemorrhage on CT/MRI
12. Clinical presentation suggests a subarachnoid hemorrhage, even if initial CT or MRI scan is normal
13. Suspicion of aortic dissection
14. Subject currently uses or has a recent history of illicit drug(s) or abuses alcohol
15. History of life threatening allergy (more than rash) to contrast medium
16. SBP >185 mmHg or DBP >110 mmHg refractory to treatment
17. Serious, advanced, terminal illness with anticipated life expectancy < 6 months
18. Pre-existing neurological or psychiatric disease that would confound evaluation
19. Presumed vasculitis or septic embolization
20. Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas)

### 3.2.3 Brain Imaging

Patients will have a non-contrast CT scan (NCCT) at hospital admission to rule out the presence of blood and estimate the Alberta stroke program early CT score (ASPECTS) that will be used to select into the trial only patients with ASPECTS ≥ 6. Concomitantly, a whole brain CT-Perfusion (CTP) will be performed before transfer of the patient to the angio suite. The protocol for CTP acquisition will be harmonized by the Neuroimaging Core Lab as described in the Appendix. Patients will then receive MT according to the general methods described below. At 10 minutes of completion of the experimental therapy the angiographic results will be recorded on anterior-posterior and lateral projections for central scoring according to the modified Treatment of Cerebral Ischemia (mTICI) grading score (Appendix). At 24 ±12 hours of randomization, a NCCT will be performed to assess the presence of early bleeding complications following ECASS3 criteria (Appendix). At 48±24 hours of randomization, a brain MRI with DWI and T2* sequences will be performed to measure the volume of the infarction, estimate the growth of the infarction and assess the presence of late bleeding complications (Appendix). If a brain MRI cannot be performed for contraindications, intolerance or unavailability, a NCCT will be indicated. The admission NCCT, admission CTP, post-MT angiography, 24h NCCT and 48h brain MRI or NCCT will be transferred to the Central Imaging Core Lab (CICL) for storage and reading within 72 hours of image acquisition (Appendix).

Other study visits and study assessments are specified in Appendix 6.5.

### 3.3 Interventions

Patients with confirmed large vessel occlusion (LVO) of the anterior, middle or posterior cerebral artery and treated with MT will receive alteplase (Actylise®) or placebo if the mTICI score at the end of MT is 2b.

All the patients will be given a 30 minutes IA infusion at a drug concentration of 0.5mg/ml. At 20 minutes of IA treatment onset, the infusion will be temporarily stopped and restarted until completion of the 30 minutes infusion only if the mTICI 2b score has not improved on control angiography. Study drug will be prepared according to the following steps:

1. Dilute 3 vials of 10 mgs (alteplase or placebo) in 30 cc of sterile water for injection (SWI), to attain a 30 cc solution at a concentration of 1mg/ml
2. Dilute this solution in 30 cc of normal saline, to attain a 60 cc solution at a concentration of 0.5mg/ml
3. Calculate the volume of cc of infusion and therefore the total dose as per the formula:
(Patient’s weight in Kgs multiplied by 0.225) multiplied by 2)

As shown in the figure, a patient of 80 Kgs will receive 36 cc of infusion for 30 min, totaling a dose of 18 mg of alteplase.

The placebo will consist of a lyophilized white powder containing 0.2 mol/L arginine phosphate, 0.01% polysorbate 80, and pH 7.4 after reconstitution.

Figure

### 3.3.1 Blinding
The solutions of alteplase or placebo are limpid, transparent and colorless. Alteplase (Actilyse 10 mg powder and solvent for solution for injection and infusion) and placebo will be provided in kind by Boehringer Ingelheim. The secondary conditioning of the investigation treatment will be performed by Alcura Health Spain S.A.

### 3.3.2 Concomitant care and interventions prohibited during the trial
Patients will receive alteplase upon hospital arrival if indicated according to each institutional protocol, and always in agreement with European Stroke Organization and national guidelines. The use of anticoagulants and dual antiplatelet therapy will not be permitted during the 24 hours after the administration of the experimental therapy.
3.4 Assignment of intervention. Allocations and sequence generation

Randomization codes will be produced by means of the PROC PLAN of the SAS system, with a 1:1 ratio of assignment between both arms, stratifying by centre, and use of IV alteplase (no or yes) in blocks multiple of 2 elements. The time of randomization will be initiated whenever a full angiogram establishes the patient has an mTICI 2b score. A "Real-Time" randomization procedure will be implemented via the CHOICE Trial Website where the clinical center staffs enter the basic baseline and eligibility information of a subject prior to enrolment. If the subject’s eligibility status is confirmed, the computer program on the server will make the treatment assignment based on the randomization algorithm specified.

3.5 Outcomes

3.5.1 Primary outcome

The primary outcome will be the proportion of patients with an improved mTICI score ten (10) minutes after the end of study treatment.

3.5.2 Secondary Outcomes

- The shift analysis of the modified Rankin Scale (mRS), at day 90. The mRS at 90 days will be analyzed using a proportional odds model (POM) that combine into single worst rank the last two categories (5: severe incapacity and 6: death).
- Infarct Expansion Ratio on DWI-MRI (continuous variable), at 24h of stroke
- Proportion of patients with excellent outcome (mRS 0-1) at day 90
- Proportion of patients with/without infarct expansion (dichotomous variable)
- Infarction Volume on DWI-MRI, at 24h of stroke onset

3.5.3 Tertiary outcomes

- mRS of 0 to 2, at day 90
- Barthel Scale score of 95 to 100, at day 90
- Ischemic worsening (≥ 4 points in the NIHSS score) within 72 hours of stroke onset not attributable to stroke recurrence
- Quality of life measured with the EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D-3L) at 90 days

3.5.4 Pre-specified subgroup analysis

Proportion of patients with improved mTICI 2b score in the following subgroups:

1. IV Alteplase use on admission (yes versus no)
2. MT started within 7.3h of symptoms onset versus MT started between 7.4h and 24h.
3. Admission serum glucose concentration<100 mg/dL versus >100 mg/dL
4. Males vs. females

### 3.5.5 Safety outcomes

1. Mortality at 90 days
2. sICH rates at 24 hours.

All ICH will be classified by a central core-lab using the ECASS3 criteria. Symptomatic ICH will be defined as per the ECASS3 definition: deterioration in NIHSS score of ≥4 points within 24 hours from treatment and evidence of any apparently extravascular blood in the brain in the 24 hours follow-up imaging scans. The incidence of any asymptomatic hemorrhage measured at 24 hours will also be compared.

### 3.5.6 Adverse events (AEs) and Serious Adverse Events (SAEs)

#### 3.5.6.1 Definitions and Classification

An **Adverse Event** (AE) is any untoward medical occurrence in a patient temporarily associated with the use of the investigational drug, whether or not considered related to the investigational drug. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of the drug, whether or not considered related to the drug.

Any AE experienced by the study subject after enrolment (equal to the time of randomization) must be recorded in the CRF.

All AEs and SAEs will be monitored and collected from the time of enrolment (defined as the time of randomization) through 90 day follow-up visit. All SAEs and SUSAR must be reported to CRA or designee within 24 hours of becoming aware of their occurrence in order to comply with regulatory reporting requirements. In the event that the eCRF is unavailable a written form sent by e-mail or fax is acceptable (the required form will be filed in the ISF).

Underlying (pre-existing) symptoms or diseases are not reported as Adverse Events (AEs) unless there is an increase in severity or frequency during the course of the investigation, but they need to be reported in the eCRF as Relevant Medical History.

Death should not be recorded as an adverse event, but should only be reflected as an outcome to another specific AE/SAE.

A qualified medical investigator must review all information available to determine the **seriousness**, **causality**, **severity** and **outcome** of the AE as well as to assess whether it
meets the criteria for classification as a serious adverse event, which requires immediate notification to the sponsor or its designated representative.

All AEs and the treatment and follow-up required must be documented in the subject’s medical records and in the eCRF.

A procedural complication may constitute an AE if it results in an untoward change from the subject’s baseline health.

**Serious Adverse Event (SAE)** is defined as an adverse event that:

a) Led to a death, injury or permanent impairment to a body structure or a body function.

b) Led to a serious deterioration in health of the subject, that either resulted in:
   - A life-threatening illness or injury, or
   - A permanent impairment of a body structure or a body function, or
   - In-patient hospitalization or prolongation of existing hospitalization, or
   - In medical or surgical intervention to prevent life-threatening illness

c) Led to foetal distress, foetal death or a congenital abnormality or birth defect.

*Note:* Planned hospitalization for pre-existing condition, or a procedure required by the Clinical Investigation Plan, without a serious deterioration in health, is not considered a serious adverse event.

Abnormal laboratory findings (e.g. clinical chemistry, hematology, urinalysis) or other abnormal assessments (e.g. ECG, vital signs) that are judged by the investigator as clinically significant will be recorded as AEs or SAEs if they meet the definition of an AE or SAE as previously defined. Clinically significant abnormal laboratory findings or other abnormal assessments that are detected during the study or are present at baseline and significantly worsen following the start of the study will be reported as AEs or SAEs.

However, clinically significant abnormal laboratory findings or other abnormal assessments that are associated with a disease reported in the medical history, unless judged by the investigator as more severe than expected for the subject’s condition, or that are present or detected at the start of the study and do not worsen, will not be reported as AEs or SAEs.

### 3.5.6.2 Recording of AEs and SAEs

When an AE/SAE occurs, it is the responsibility of the investigator to review all documentation (e.g. hospital progress notes, laboratory, and diagnostic reports) relative to the event. The investigator will then record all relevant information regarding an AE/SAE into the CRF. It is not acceptable for the investigator to send photocopies of the subject’s medical records to the sponsor in lieu of completion of the appropriate AE/SAE CRF pages and forms. For each adverse event, start and stop dates, action taken, outcome, intensity
and relationship to study drug (causality) must be documented. If an AE changes in frequency or intensity during a study, a new entry of the event must be made in the CRF. The investigator will attempt to establish a diagnosis of the event based on signs, symptoms, and/or other clinical information. In the absence of a diagnosis, the individual signs/symptoms should be documented. All details of any treatments initiated due to the adverse event should be recorded in the subject’s notes and the CRF/form.

### 3.5.6.3 Prompt Reporting of SAEs

SAEs require immediate action. Once an investigator becomes aware that an SAE has occurred, he/she will immediately notify the clinical coordinator via telephone within one working day. The study SAE form must be completed as thoroughly as possible with all available details of the event, signed by the investigator (or appropriately qualified designee), and reported into the eCRF or to the study manager, within one working day of first becoming aware of the event. The equivalent SAE page should be filled in on the CRF.

If the investigator does not have all information regarding an SAE, he/she will not wait to receive additional information before reporting the event and completing the form. The form will be updated when additional information is received.

The investigator will always provide an assessment of causality at the time of the initial report. In accordance with local IEC requirements, the investigator must also notify their Ethics Committee of any SAEs according the guidelines of the Ethics Committee. The investigator and others responsible for subject care should institute any supplementary investigations of SAEs based on their clinical judgment of the likely causative factors. This may include seeking further opinion from a specialist in the field of the adverse event or requesting extra tests. If a subject dies, any post-mortem findings, including histopathology will be provided if available. No medical help, diagnosis, or advice should be withheld from the subject due to an inability to contact the study manager/medical monitor.

When entered a SAE into the eCRF, an alert will be received by the designed persons (i.e.: monitor)

### 3.5.6.4 Evaluating AEs and SAEs

#### 3.5.6.4.1 Assessment of Intensity

The investigator will make an assessment of intensity for each AE and SAE reported during the study. The assessment will be based on the investigator’s clinical judgement. The intensity of each AE and SAE recorded in the CRF or SAE form should be assigned to one of the following categories:
**Mild**  
Awareness of sign, symptom, or event, but easily tolerated

**Moderate**  
Discomfort enough to cause interference with usual activity and may warrant intervention

**Severe**  
Incapacitating with inability to do normal daily living activities or significantly affects clinical status, and warrants intervention

An AE that is assessed as severe should not be confused with an SAE. Severity is a category utilised for rating the intensity of an event; and both AEs and SAEs can be assessed as severe. An event is defined as "serious" when it meets one of the pre-defined outcomes as previously described in Section 3.5.7.1 Definitions and Classification.

### 3.5.6.4.2 Assessment of Causality

The Principal Investigator or a medically-qualified designee must assess the relationship between investigational drug and the occurrence of each AE/SAE. The investigator will use clinical judgment to determine the relationship. Alternative causes, such as natural history of the underlying diseases, concomitant therapy, other risk factors, and the temporal relationship of the event to the investigational drug administration will be considered and investigated. The investigator will also consult the study drug information in the determination of his/her assessment. The causal relationship to the study drug assessed by the Investigator (or medically qualified delegate) should be assessed using the following classifications:

**Unrelated**  
No temporal association, or the cause of the event has been identified, and the event determined to be due to a concurrent illness or effect of another drug reaction and is not related to the study drug.

**Possibly related**  
Temporal association, but other aetiologies are likely to be the cause; however, involvement of the study drug cannot be excluded based on available information

**Probably related**  
Temporal association and there is no other reasonable medical explanation for the event based on available information

### 3.5.6.4.3 Assessment of Expectedness

Expected adverse reaction, the nature or severity of which is consistent with the applicable study drug information (e.g. Investigators' Brochure) for an unapproved medicinal product.
Unexpected adverse reaction, the nature or severity of which is not consistent with information in the study drug information.

3.5.6.4.4 Follow-up of AEs and SAEs

After the initial AE/SAE report, the investigator is required to actively follow each subject and provide further information into the eCRF pertinent forms on the subject's condition. All AEs and SAEs documented at a previous visit/contact and are designated as on-going, will be reviewed at subsequent visits/contacts. All AEs and SAEs will be followed until resolution, until the condition stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up. Once resolved, the appropriate AE/SAE CRF page(s) will be updated. The investigator will ensure that follow-up includes any supplemental investigations as may be indicated to elucidate the nature and/or causality of the AE or SAE. This may include additional laboratory tests or investigations, or consultation with other health care professionals. New or updated information will be recorded on the originally completed SAE form, with all changes signed and dated by the investigator.

3.6 Statistical methods

3.6.1 General Remarks

The statistical analysis will be carried out in accordance with the principles specified in the International Conference on Harmonization (ICH) Topic E9 (CPMP / ICH / 363/96)\(^\text{45}\). A detailed Statistical Analysis Plan (SAP)\(^\text{46}\) agreed upon by the sponsor and the Project Statistician will be available before the un-blinding of the data base. This SAP will follow the general regulatory recommendations given in the ICHE9\(^\text{47}\) guidance, as well as other specific guidance on methodological and statistical issues\(^\text{48}\). Also, it will stick to the recommendations given by the consensus documents of the scientific journals\(^\text{49,50,51}\) to improve reliability and value of medical research literature by promoting transparent and accurate reporting of clinical research studies.
The SAS System\(^\text{52}\) (Release 9.4, or an upgraded version), or equivalent validated statistical software, will be the statistical software used to analyze the data sets. A summary of the overall approach to statistical analysis is presented hereafter.

3.6.2 Sample size calculation

A sample size of 100 patients per treatment arm in a 1:1 allocation will have >95% statistical power for the primary outcome (5% of improved TICI score control vs 60% in experimental) for a two-sided 5% alpha, taken into account a 5% of the sample lost to
follow up. This sample size will also guarantee around 80% power for most of the secondary outcomes with at least 90 valid patients per arm, as shown in the table below:

<table>
<thead>
<tr>
<th>Primary Outcome</th>
<th>Control</th>
<th>Experimental</th>
<th>OR / P(Noether)</th>
<th>Differences: % or Median</th>
<th>Power³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Proportion of patients with a mTICI improvement %</td>
<td>5%</td>
<td>60%</td>
<td>0.04</td>
<td>% diff: 55%</td>
<td>&gt;&gt;95%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Secondary Outcomes with at least 80% statistical power</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infarct Expansion Ratio on DWI-MRI</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Categorical shift in mRS, at day 90</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>% of patients with excellent outcome (mRS 0-1) %</td>
</tr>
<tr>
<td>Proportion of patients with no infarct expansion %</td>
</tr>
</tbody>
</table>

OR: Odds ratio; IQR: Interquartile range (P25-P75)
P(Noether): Probability that an observation in the Experimental arm has a better value than an observation in the Control arm
1: Estimated from data of Chamorro et al. 2017
2: Estimated the work of the MR Stroke Collaborative Group 2006
3: Sample sizes estimated using nQuery v7.0 software, relying on Noether for the Wilcoxon-Mann-Whitney approach for ordinal and non-parametric continuous data, and on Machin & Campbell and Fleiss for binary endpoints

3.6.3 Data Blind Review (DBR)

The Data Blind Review (DBR) will be performed before lock of database. Data will be examined for compliance with the trial protocol by the monitor and the data manager. Deviations will be sent to the project statistician to plan listings for the Data Blind Review (DBR). The objective is to carry out the population selection and definition of the final study populations as well as a preliminary assessment of the quality of the trial data.

3.6.4 Analysis populations

There will the following analysis populations for this study:

1) Modified Full Analysis Set (mFAS): All patients who are randomized into the study and who have received the investigational medicinal product (IMP) will be included in the mFAS population.

2) Per Protocol Population: Per protocol (PP) patient sets will be defined as those patients included in the mFAS set without major protocol deviations that might impact the study’s main assessments. These deviations will be assessed during the data review prior to database lock.

3) The Safety population is defined as all randomized participants who received the investigational drug (any of the three arm treatment). In this study the Safety
The population will have the same definition than the mFAS subset and thus, all safety analysis will be conducted on the mFAS population.

The precise reasons for excluding participants from each population will be fully defined and documented independently of the randomization codes during the Data Blind Review and before the database lock.

### 3.6.5 Randomisation Procedure
Randomisation codes were produced by means of the PROC PLAN of the SAS system, with a 1:1 ratio of assignment between both arms, stratifying by centre, and use of IV alteplase (no or yes), in blocks multiple of 2 elements. The codes will released to the manufacturer site, which is independent from the study sponsor and be managed from the eCRF in a blinded manner.

### 3.6.6 Inferential Analysis
No inferential analysis will be performed for the baseline comparability. The inferential analyses will be limited to the efficacy variables, and the adverse events. For adverse events the following criteria is predefined: bleeding events (major, minor, overall), organ-system according to the MedDRA codes, and the MedDRA preferred-terms with at least 10% overall prevalence or at least the 5 more prevalent preferred-terms.

#### 3.6.6.1 Primary endpoint
The proportion of patients with an improved mTICI score ten (10) minutes after the end of study treatment will be estimated using a log-binomial regression model including the stratification variables, except centre. In the unexpected event that the model does not fit, the Poisson regression model with long-link and robust variance estimator will be used instead.

#### 3.6.6.2 Secondary endpoints and safety outcomes

**Binary outcomes**

Binary efficacy and safety (mortality at 90 days and sICH rates at 24 hours) outcomes will be analysed as described for the primary endpoint.

**Shift outcomes**

The shift analysis of the modified Rankin Scale (mRS) will be analyzed using the proportional odds model, combining into single worst rank the last two categories (5: severe incapacity and 6: death) and the stratification variables except centre. The common
odds ratio can also be interpreted as the average shift over the total ordinal outcome scale caused by the treatment under study\textsuperscript{65-67}. The stratified non-parametric van Elteren test\textsuperscript{68}, using modified ridit scores which is as a direct extension of the extension of the Wilcoxon's rank-sum test for 2-samples, will be calculated as a sensitivity analysis to compare the modified Rankin scale as an ordinal rather than a binary outcome, without assuming proportional odds\textsuperscript{69,70}.

The median of the absolute values the 95% confidence interval (95%CI) will calculated using the Hodges-Lehmann methods (i.e. median of all cross differences between treatments based on the Mann-Whitney distribution)\textsuperscript{71,72}.

**Continuous outcomes**

Continuous variables will be analyzed using Mixed Models\textsuperscript{73}, including in the model the baseline measurement, the stratification variables except centre, treatment as well as the interaction between treatment and time, declaring time as categorical. The variance-covariance matrix will be fixed initially as unstructured. If this analysis fails to converge, the following structures will be tested in the following order until convergence: AR(1) (Auto-Regressive first order), Toeplitz and CS (Compound Symmetry). Contrasts between dialysis groups will be performed by time-point. The treatment effect will be estimated through adjusted means –Least Square Means (LSMeans) – its standard error – Standard Error of Mean (SEM)- and its 95%CI. Differences between treatments will be estimated through the differences between LSMeans, SEM and 95%CI.

**3.6.6.3 General strategy for the rest of variables**

The rest of variables will be analyzed according to the following strategy: the Fisher’s exact test to compare categorical variables, the dependent or independent t-test for continuous Gaussian-distributed variables and the Mann-Whitney for ordinal and non-Gaussian continuous data. The survival function for death as well as the median [95% confidence interval -95%CI-] will be estimated by means of the Kaplan-Meier method. Group comparisons will be conducted using the stratified the log-rank test and, hazard ratios -HR-(95%CI) were taken from the Cox model\textsuperscript{74}.

**3.6.7 Multiplicity adjustments and interim analysis**

The analysis will follow the principles specified in the ICHE9 \textsuperscript{75} and the CPMP/EWP/908/99\textsuperscript{76} Points to Consider on Multiplicity issues in Clinical Trials guidelines. No interim analysis is planned for this study. For this reason, there is no statistical criterion for early termination of the trial.
3.6.8 Handling of missing data

The handling of missing data will follow the principles specified in the ICH-E9\textsuperscript{32} and the CPMP/EWP/1776/99 Rev1. Guideline on Missing Data in confirmatory trials Guidelines\textsuperscript{77}. Missing data on the primary outcome or other binary efficacy secondary outcomes will be considered as failures, irrespectively to the reason for missingness. For mRS the worst case imputation will be used (i.e. imputing the worst category of the scale). With regards to the continuous variables, mixed models\textsuperscript{78,79,80} are robust to the presence of missing at random (MAR) and conducts the analysis with all participants despite the presence of missingness. Of note, this method calculates the estimations based on the variance-covariance structure but without any formal imputations.

No formal imputations will be performed for the rest of variables and the analyses will be based on the Available Data Only (ADO) approach.

3.6.9 Subgroup analysis

The following 4 subgroups are declared of special interest and they will be investigated for the proportion of patients with improved mTICI 2b score:

- IV Alteplase use on admission (yes versus no)
- MT started within 7.3h of symptoms onset versus MT started between 7.4h and 24h.
- Admission serum glucose concentration \(<100 \text{ mg/dL} \) versus \(>100 \text{ mg/dL} \)
- Males vs. females

No other subgroup analyses are planned. In case of any post-hoc subgroup analysis, they will be justified and identified as data-driven and, they will follow the principles and regulatory recommendations\textsuperscript{81}.

The following strategy will be conducted before splitting the analysis into subgroups:

1. Test of the overall treatment effect
2. Test of the treatment-by-subgroup interaction at the 10\% level of significance
3. Test of the treatment effect in each subgroup category

If the three criteria are met, then the subgroup analysis will be given the maximal level of evidence for this analysis. However, this subgroup analysis is predefined as exploratory and the interpretation should be taken with caution. If any of the criterion are not meet, the chances of type I error increase are higher and this will have an impact in the interpretation.
3.7 Study feasibility

The sites participating in CHOICE performed in 2016 575 MT procedures that were registered in the Sistema Online d'Informació de l'Ictus Agut (SONIIA) Registry. For pooled data analysis of five RCTs of MT reported an average rate of 38% of mTICI2b score at the end of MT, these figures allow to estimate that the total potential annual accrual rate at the participating sites is of 216 patients per year. Conservatively, the adjustment for the effects of competing trials, rates of patient’s consent, and unforeseen causes, allow to give a conservative estimation of 108 patients included in the trial each year. Accordingly, total inclusion of the patients could be completed in 22 months (Table 2).

Table 2 Estimated annual accrual rate by participating center in CHOICE

<table>
<thead>
<tr>
<th>Hospital</th>
<th>MT annual activity</th>
<th>Fulfilling CHOICE criteria</th>
<th>50% adjustment for competing trials and others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital Clinic de Barcelona (HC)</td>
<td>135</td>
<td>51</td>
<td>26</td>
</tr>
<tr>
<td>Hospital U. de Bellvitge (HB)</td>
<td>142</td>
<td>54</td>
<td>27</td>
</tr>
<tr>
<td>Hospital Vall d’Hebron (HVH)</td>
<td>172</td>
<td>65</td>
<td>33</td>
</tr>
<tr>
<td>Hospital Santa Creu i Sant Pau (HSP)</td>
<td>17</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>Hospital del Mar (HM)</td>
<td>26</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>Hospital Germans Trias i Pujol (HGTP)</td>
<td>83</td>
<td>31</td>
<td>15</td>
</tr>
<tr>
<td>TOTAL pts/yr</td>
<td>575</td>
<td>216</td>
<td>108</td>
</tr>
</tbody>
</table>

4. DATA MANAGEMENT / MONITORING AND QUALITY CONTROL

4.1 Data collection methods

An electronic Case Report Form (eCRF) will be completed for each study subject, summarizing all clinical screening and study data. Subjects will only be referred to in the eCRF by their subject number and initials in order to retain subject confidentiality.

4.2 Data management

Data will be captured in an eCRF and the Investigator is responsible for ensuring the prompt and accurate reporting of study data into the eCRF. The eCRF is reachable via the internet at any time. The system uses a secured data connection (with Secure-Sockets-Layer protocol, SSL) to transfer the data from the study centres to the central database. Data management documentation will be prepared by the Medical Statistics CRO in charge of the eCRF and data management.

The data collection will be monitored by external qualified staff and entered into a remote access database (Electronic Case Record Form eCRF). The eCRF will be managed by the
IDIBAPS. This system will meet the general\textsuperscript{82} and specific\textsuperscript{83} standards of Good Clinical Practice and the highest requirements of computer validation\textsuperscript{84,85,86,87}, with restricted user-level access, equipped with filters to detect inconsistencies and traceability of all information to closure end thereof. Any data transfer will be done using secure SSL connection with encryption. Export for archiving of the clinical database including audit trails in hard- and software independent storage formats will be provided by IDIBAPS.

Furthermore the technical support will be provided for the study centers during the study duration (administration of logins, roles and rights).

In case of scheduled, unscheduled analyses or other needed reports the data will be exported from the database. In a further process these data will be checked, prepared and delivered for these purposes.

Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).

When the database has been declared to be complete and accurate, the database will be locked. Any changes to the database after that time can only be made by written agreement between the sponsor and the Medical Statistics core facility and with a sound justification and full traceability of the process.

At the end of the study the entire database will be exported. The final data management process contains the plausibility, consistency and range checks of the data. The missing data will be identified as well. Data Clarification Forms will be generated for data clarification.

After all data management processes are completed, the cleaned data will be available for the statistical analysis. The final data will be delivered in a defined SAS data format, including a data management report as well.

### 4.3 Data monitoring

Study monitoring will be performed by ANAGRAM-ESIC. Best conduct of the study will be ensured through frequent contacts by phone and in person with the responsible Investigator, in accordance with ANAGRAM-ESIC Standard Operating Procedures, with the purpose of facilitating the work and fulfilling the objectives of the study. Site visits will enable the Monitor to maintain current, personal knowledge of the study through review of the records, comparison with source documents, and observation and discussion of the conduct of the study with the Investigator. The Monitor is responsible for monitoring
adherence to the Protocol and completion of the eCRF. They are also responsible for the organization, monitoring, supply of study materials and quality assurance of the study. In order to ensure the accuracy of data, direct access to source documents by the representatives of both the Study Monitor and Regulatory Authorities is mandatory.

The trial will be managed by a Steering Committee, with Chair, Ángel Chamorro. There will also be an independent Data Safety Monitoring Board (DSMB) — chaired by Tudor Jovin. The Steering Committee comprising investigators from each participating centre and a Neurointerventional Committee, with Chair Jordi Blasco, will comprise neurointerventionalists from each participating centre. A Neuroimaging Core Lab with Chair Luis San Román, will manage all the imaging data collected in the trial. A Patient’s recruitment Board with Chair Monica Millán will supervise that patient’s accrual in the trial abide to anticipated estimations.

4.4 Screening log
Each collaborating site is requested to complete a screening log of all patients treated with mechanical thrombectomy who are not included in the trial. The log is used to monitor recruitment and identify barriers to recruitment at that site.

4.5 Data auditing
The Steering Committee has assigned a CRO to this study whose duties are to aid the P.I. and the Steering Committee members in the maintenance of complete, legible, well organized, and easily retrievable data. Personnel from CRO will ensure that the study complies with relevant Good Clinical Practices (GCPs). Periodic monitoring visits will be made throughout the investigation to assure that the investigator’s obligations are being fulfilled. Monitoring visits will be performed to verify data accuracy and ensure queries are resolved.

4.6 Independent Committees
- **Data Safety Monitoring Board (DSMB)**
An independent Data Safety Monitoring Board will be established. The purpose of the DSMB is to review, on a regular basis, accumulating data from the on-going trial. The DSMB will be composed of two stroke neurologists and a statistician who are not participating in the study and are not affiliated with the sponsor. The role of the DSMB will be to: 1/Review the occurrence of AEs and 2/ Make recommendations to the Executive Committee regarding safety of the study. A strict control of predefined AEs and SAEs will be ensured through monitoring by the CRO.
A Data Safety Monitoring Board (DSMB) will follow-up the safety of the study. Although the DSMB will review data in an unblinded manner, the date of the SAP closure will be set before the first unblinded review so that the study will maintain the integrity and will avoid any operational bias. Any potential analysis amendment will be traced and justified, if applicable. The study followed the regulatory recommendations regarding the functions and procedures of these committees.

- **Independent Imaging Core Lab (ICL)**

An independent Imaging Core Lab will be established. The purpose of the ICL is to review, on a regular basis, accumulating imaging data from the ongoing trial. The ICL will be composed of two neuro-radiologists, a stroke neurologist and one physicist. The role of the DSMB will be to: 1/ Review the occurrence of AEs and 2/ Make recommendations to the Executive Committee regarding safety of the study. A strict control of predefined AEs and SAEs will be ensured through monitoring by the CRO.

**4.7 Training of investigators and site personnel**

The training of the Investigator, and appropriate clinical site personnel will be the responsibility of the Study Coordinating Group and may be conducted during local investigator meeting, a site initiation visit, or other appropriate training sessions. Training will include, but not be limited to, the study protocol, eCRF completion, neurological scale evaluation and site personnel responsibilities. All Investigators and site personnel that are trained must have their training documented.

Prior to the initiation of the study and subject enrolment, the Study Coordinating Group or designee will visit each site where the trial is conducted. The Sponsor or designee will ensure that the site personnel are informed about and understand the clinical study requirements.

Specific training will be offered to research team professionals.

**5. ETHICS AND DISSEMINATION**

**5.1 Research Ethics approval**

Clinical Research Ethics Committee of the hospital Clinic, which will act as the CEIm for this research project and approve Study Protocol and the patient information sheet and informed consent form, as applicable to this type of regulation studies. The Clinical Research Ethics Committee will also approve any revision or modification of the research protocol, the informed consent form or the patient information sheet.

This study will be conducted according to the provisions of the RD 1090/2015 of December 4, which regulates clinical drug trials, the Royal Legislative Decree 1/2015 of July 24, Law
on guarantees and rational use of medicines and medical devices, the Royal Decree 577/2013 of 26 July, which regulates pharmaco-surveillance and, all in what is applicable to them, and the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013) and good clinical practice guidelines.

The trial will be conducted in agreement with the International Conference on Harmonization (ICH) guidelines on Good Clinical Practice (GCP).

5.2 Consent

Patient or his/her representative will sign the specific approved version of informed consent form at hospital arrival before participating in the clinical trial and inclusion of its clinical data into the electronic CRF.

A signed informed consent, indicating full and complete understanding of the study, should be obtained prior to initiating the randomization process or any study procedures, unless the site has been granted an explicit waiver of consent or allowance for verbal consent from the CEIm. This specific allowance of verbal consent will be requested by a telephone call in presence of a waiver (neurologists) for patients that are transferred from other centers without accompanying relatives in the ambulance, in order to not delay patient’s allocation.

Given the characteristics of the study that will be carried out in the context of an emergency situation, the basic ethical principles: autonomy, beneficence, non-maleficence and justice have been taken into consideration:

- Beneficence and non-maleficence are fully respected, being both alternatives according to the best treatment criteria.

- Patients’ autonomy is respected to make their own decisions regarding their subsequent monitoring.

- Distributive justice is respected since the study is equally based on all patients who meet the selection criteria and excludes differences based on social or economic levels/conditions.

Written Informed Consent must be given after the context of the study has been fully explained in a language that is easily understood by the subject or his/her representative. The subject or his/her representative must also be given the opportunity to ask questions and have those questions answered to his/her satisfaction.

Written Informed Consent must be recorded appropriately by means of the subject’s, or his/her representative dated signature. The consent process must be documented in the subject’s medical chart.
5.3 Confidentiality

Investigators, who use information about the health of their research participants, are required except in specific circumstances, to get written permission to use their participant’s protected health information (PHI) for the research study. Each participating clinical center is expected to comply with its individual performance site’s requirements established for compliance of the local confidentiality policies.

All study data will be collected in an anonymous way, through the eCRF and no personal data will be extracted from investigational sites in any case.

5.4 Record Retention

The Investigator will maintain all essential trial documents and source documentation, in original format, that support the data collected on the study subjects in compliance with the ICH/GCP guidelines. Documents must be retained for at least 25 years as per Spanish and European guidelines.

The Investigator will take measures to ensure that these essential documents are not accidentally damaged or destroyed. If for any reason the Investigator withdraws responsibility for maintaining these essential documents, custody must be transferred to an individual who will assume responsibility. Sponsor must receive written notification of this custodial change.

5.5 Dissemination policy

A writing committee will be formed to review and publish the data from the study. This committee will consist of the Steering Committee and a subset of investigators. The writing committee will write/review all drafts of abstracts and full-length manuscripts and will choose the appropriate journal (for manuscripts) or meeting (for abstracts) for submission.

The CHOICE Steering Committee commits that when the study is completed, the data from this study will be published within 3 months, regardless of the outcome of the study and the trial will be listed on the clinical trials website.

All information concerning the CHOICE trial supplied to the investigators by the Steering Committee and not previously published is considered confidential and shall remain the sole property of the CHOICE Steering Committee. The investigator agrees to use this information only in accomplishing the study and will not use it or the data generated from the study for other purposes without first obtaining written authorization from CHOICE Steering Committee.

It is understood that CHOICE Steering Committee may disclose this information as required to other CHOICE clinical investigators or to government regulatory agencies. The
investigator understands that she or he has the obligation to provide complete test results and all data collected during this study to the Steering Committee.
### 6. APPENDICES

#### 6.1 Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AE</td>
<td>Adverse Event</td>
</tr>
<tr>
<td>AEMPS</td>
<td>Agencia Española del Medicamento y Productos Sanitarios</td>
</tr>
<tr>
<td>AHA/ASA</td>
<td>American Heart Association/American Stroke Association AMI Acute Myocardial Infarction</td>
</tr>
<tr>
<td>ASPECTS</td>
<td>Alberta Stroke Program Early CT score</td>
</tr>
<tr>
<td>CRF</td>
<td>Case Report Form</td>
</tr>
<tr>
<td>CT</td>
<td>Computerized Axial Tomography</td>
</tr>
<tr>
<td>CTA</td>
<td>Computerized Axial Tomography Angiography</td>
</tr>
<tr>
<td>CTP</td>
<td>Computerized Tomography Perfusion</td>
</tr>
<tr>
<td>CRO</td>
<td>Contract Research Organization</td>
</tr>
<tr>
<td>EMS</td>
<td>Emergency Management of Stroke</td>
</tr>
<tr>
<td>GCP</td>
<td>Good Clinical Practice</td>
</tr>
<tr>
<td>IA</td>
<td>Intra-arterial</td>
</tr>
<tr>
<td>ICA</td>
<td>Internal Carotid Artery</td>
</tr>
<tr>
<td>ICH</td>
<td>Intra-cerebral Hemorrhage</td>
</tr>
<tr>
<td>IMS III</td>
<td>Interventional Management of Stroke Trial III</td>
</tr>
<tr>
<td>INR</td>
<td>International Normalized Ratio</td>
</tr>
<tr>
<td>ISF</td>
<td>Investigator’s Site Folder</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>IVT</td>
<td>Intravenous Thrombolysis</td>
</tr>
<tr>
<td>LVO</td>
<td>Large Vessel Occlusion</td>
</tr>
<tr>
<td>MAR</td>
<td>Missing at random</td>
</tr>
<tr>
<td>MCA</td>
<td>Middle Cerebral Artery</td>
</tr>
<tr>
<td>MCD</td>
<td>Mechanical Clot Disruption</td>
</tr>
<tr>
<td>mFAS</td>
<td>Modified Full Analysis Set</td>
</tr>
<tr>
<td>MRA</td>
<td>Magnetic Resonance Angiography</td>
</tr>
<tr>
<td>mRS</td>
<td>Modified Rankin Scale</td>
</tr>
<tr>
<td>MT</td>
<td>Mechanical thrombectomy</td>
</tr>
<tr>
<td>mTICI</td>
<td>Modified Treatment In Cerebral Infarction scale</td>
</tr>
<tr>
<td>M1</td>
<td>Proximal segment of the MCA from the origin to bifurcation/trifurcation, also known as horizontal or sphenoidal segment</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Form</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>NIHSS</td>
<td>National Institute of Health Stroke Scale</td>
</tr>
<tr>
<td>OR</td>
<td>Odds Ratio</td>
</tr>
<tr>
<td>PCI</td>
<td>Percutaneous Coronary Intervention</td>
</tr>
<tr>
<td>Pp</td>
<td>Per Protocol</td>
</tr>
<tr>
<td>PROBE</td>
<td>Prospective randomized open blinded end-point</td>
</tr>
<tr>
<td>RACE</td>
<td>Rapid Arterial occlusion Evaluation</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomized controlled trial</td>
</tr>
<tr>
<td>RD</td>
<td>Royal Decree</td>
</tr>
<tr>
<td>rt-PA</td>
<td>Recombinant tissue Plasminogen Activator</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious Adverse Event</td>
</tr>
<tr>
<td>SICH</td>
<td>Symptomatic Intra-Cerebral Hemorrhage</td>
</tr>
<tr>
<td>SONIIA</td>
<td>Sistema ONline d'Informació de l'Ictus Agut</td>
</tr>
<tr>
<td>SUSAR</td>
<td>Suspected Unexpected Serious Adverse Reaction</td>
</tr>
<tr>
<td>SWFI</td>
<td>Sterilized Water for Injection</td>
</tr>
</tbody>
</table>
6.2 INFORMED CONSENT

ATTACHED AS A SEPARATE DOCUMENT
6.3 Modified Rankin scale

Modified Rankin Scale-Structured Interview (MRS-SI)

0 = No symptoms at all; no limitations and no symptoms.

1 = No significant disability; symptoms present but not other limitations. Question: Does the person have difficulty reading or writing, difficulty speaking or finding the right word, problems with balance or coordination, visual problems, numbness (face, arms, legs, hands, feet), loss of movement (face, arms, legs, hands, feet), difficulty with swallowing, or other symptom resulting from stroke?

2 = Slight disability; limitations in participation in usual social roles, but independent for ADL. Questions: Has there been a change in the person's ability to work or look after others if these were roles before stroke? Has there been a change in the person's ability to participate in previous social and leisure activities? Has the person had problems with relationships or become isolated?

3 = Moderate disability; need for assistance with some instrumental ADL but not basic ADL. Question: Is assistance essential for preparing a simple meal, doing household chores, looking after money, shopping, or traveling locally?

4 = Moderately severe disability; need for assistance with some basic ADL, but not requiring constant care. Question: Is assistance essential for eating, using the toilet, daily hygiene, or walking?

5 = Severe disability; someone needs to be available at all times; care may be provided by either a trained or an untrained caregiver. Question: Does the person require constant care?

6.4 **Angiographic assessment: The mTICI score**

The Thrombolysis in Cerebral Infarction (TICI) scale was originally proposed in a position statement that attempted to standardize clinical trial design and reporting for IAT.\(^{89,90}\). The TICI scale specifically addresses the extent of tissue reperfusion, as represented by the capillary blush on DSA. TICI is graded by visually estimating how much of the initial antegrade capillary blush defect (or target downstream territory [TDT]) is reperfused (numerator). The TICI scale distinguishes no perfusion (TICI grade 0; Figure 2), minimal flow past the occlusion but no perfusion (grade 1; Figure 3), minor partial reperfusion (grades 2a; Figures 4 and 5), major partial reperfusion (2b; Figure 2), and complete reperfusion without any flow defects (grade 3; Figures 3 and 4). The original TICI system defined TICI 2b as restoration of more than two thirds of the TDT. This is in contrast to the subsequent modification (modified treatment in cerebral ischemia [mTICI]) introduced by the IMS investigators, which uses a threshold of more than half of the TDT.\(^{91}\) The advantage of mTICI is its simplicity (ease of visually estimating 1/2 versus 2/3 reperfusion), and previous work has demonstrated excellent inter-rater agreement for distinguishing <50% versus ≥50% reperfusion of the downstream territory.\(^{92}\)

![Fig 2](image)

**Top**, Anteroposterior (first 2 boxes) and lateral (last 2 boxes) in an early arterial and late capillary phases depicting TICI 0 at baseline. **Bottom**, Same phases depicting TICI 2b after intra-arterial therapy. Black arrow indicating the target arterial lesion (TAL): middle cerebral artery/M1 horizontal segment occlusion (TAL) distal to the lenticulostriate (LS). Black half circles approximate the target downstream territory (TDT; the presumed area supplied by the TAL).
**Top**, Anteroposterior *(left)* and lateral *(right)* in an early arterial and late capillary phases depicting TICI 1 at baseline. **Bottom**, Same phases depicting TICI 3 after intra-arterial therapy. Black arrow indicating the target arterial lesion (TAL): middle cerebral artery/M1 horizontal segment occlusion (TAL) distal to the lenticulostriate (LS). Black half circles approximate the target downstream territory (TDT; the presumed area supplied by the TAL). Ischemic arteriovenous shunting is noted with opacification of straight sinus *(right bottom corner).*

Fig 4

**Top**, Anteroposterior *(first 2 boxes)* and lateral *(last 2 boxes)* in an early arterial and late capillary phases depicting thrombolysis in cerebral infarction (TICI) 0 at baseline. **Bottom**, Same phases depicting TICI 3 after IAT. Black arrow indicating the target arterial lesion (TAL): Distal ICA proximal to the ophthalmic artery. Black half circles approximate the
target downstream territory (TDT; the presumed area supplied by the TAL). Early ischemic arteriovenous shunting is noted in the right lower corner.

**Fig 5**

*Top*, Anteroposterior (first 2 boxes) and lateral (last 2 boxes) in an early arterial and late capillary phases depicting TICI 0 at baseline. **Bottom**, Same phases depicting TICI 2a after intra-arterial therapy. Black arrow indicating the target arterial lesion (TAL): middle cerebral artery/M1 horizontal segment occlusion (TAL) distal to the lenticulostriate (LS). Black half circles approximate the target downstream territory (TDT; the presumed area supplied by the TAL).

**Fig 6**

*Top*, Anteroposterior (first 2 boxes) and lateral (last 2 boxes) in an early arterial and late capillary phases depicting TICI 0 at baseline. **Bottom**, Same phases depicting TICI 2a
after intra-arterial therapy. Black arrow indicating the target arterial lesion (TAL): middle cerebral artery/M1 horizontal segment occlusion (TAL) distal to the lenticulostriate (LS). Black half circles approximate the target downstream territory (TDT; the presumed area supplied by the TAL).
## 6.5 Study assessments

<table>
<thead>
<tr>
<th>Assessments</th>
<th>Baseline information</th>
<th>Procedure/ Allocation</th>
<th>Follow up 24h (+/−12h) post-randomization</th>
<th>Follow up 48h (+/− 24h) post-randomization</th>
<th>Follow up 5 days (±2 d) post-random, or discharge (whatever occurs first)</th>
<th>Follow up 90 days (±14 d) post-random</th>
</tr>
</thead>
<tbody>
<tr>
<td>Admission Details</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographics</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical History</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility Criteria</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed Consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Randomization</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood test</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mRS</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NIHSS assessment</td>
<td>X</td>
<td>C</td>
<td>C</td>
<td>C</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCCT</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CT-P</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angiogram</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinded Study medication administration</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-MT angiography</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI (DWI/T2 sequences) Or NCCT if MRI not possible</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stroke etiology</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Procedure Details including mTICI score 10min after end of study treatment (primary outcome)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Barthel Scale</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EuroQol EQ-5D</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(S) AEs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 This mRS score should be based on subject’s score prior to the stroke symptom onset.

Ⓒ To be done by an accredited local evaluator
6.6 Bibliography


Soares BP, Chien JD, Wintemark M. MR and CT monitoring of recanalization, reperfusion, and penumbra salvage: everything that recanalizes does not necessarily reperfuse! Stroke 2009;40:S24–27


Soares BP, Chien JD, Wintemark M. MR and CT monitoring of recanalization, reperfusion, and penumbra: everything that recanalizes does not necessarily reperfuse! Stroke 2009;40:S24–27


EMEA Scientific Guidelines for Human Medicinal Products, Clinical Efficacy and Safety Guidelines, General Guidelines.URL:


51 EQUATOR-network (Enhancing the Quality and Transparency of Health Research). URL: http://www.equator-network.org/resource-centre/library-of-health-research-reporting/, last access: 12-Jan-2018


53 Chamorro et al 2017. Full brain perfusion and no less should be the target of endovascular therapy in acute stroke. (Submitted for publication)


83 Good Clinical Data Management Practice, Version 4, Society for Clinical Data Management (SCDM), October 2005


